Blood-Based Biopsy Can Predict Breast Cancer Recurrence

TON Web Exclusives - Breast Cancer

In the near future, a blood test that measures the number of tumor cells circulating in the blood, sometimes referred to as a “liquid biopsy,” may be used to predict the chance that breast cancer may recur. In a recent study, measuring circulating tumors cells (CTCs) in patients with metastatic breast cancer using a test cleared by the FDA (CELLSEARCH®) was found to be a biomarker that predicted late recurrence among patients with hormone receptor (HR)-positive, HER2-negative early breast cancer.

In this population of patients, late recurrences (defined as those that occur ≥5 years after initial diagnosis) account for approximately 50% of recurrences in HR-positive breast cancers, noted the study’s lead investigator Joseph A. Sparano, MD, Associate Director for Clinical Research, Montefiore Einstein Center for Cancer Care, Albert Einstein Cancer Center, New York, NY.

The results from this study provide “proof of concept” that the presence of CTCs is a biomarker for late recurrence of disease.

“To our knowledge, this is the first report showing that a liquid-based biomarker is robustly prognostic for late recurrence,” said Dr Sparano.

The data also support the concept that therapy for patients might be tailored based on the blood biomarker test results.

This study, the details of which were presented at the 2017 San Antonio Breast Cancer Symposium, included 546 patients drawn from a larger study that tested the effect of adding bevacizumab (Avastin) to chemotherapy as adjuvant treatment following surgery. The patients selected had no recurrence of breast cancer 4.5 to 7.5 years after an initial diagnosis of HER2-negative stage II-III disease.

Thirty-five percent of patients who had blood samples were HR-negative. Eighty-eight percent of patients with estrogen receptor–positive disease were taking endocrine therapy at the time of their CTC sample. At a follow-up of 1.8 years, 4.0% of HR-positive patients and 0.5% of HR-negative patients had a breast cancer recurrence.

Overall, 4.8% of patients had a positive CTC assay result, including 5.1% of HR-positive patients and 4.1% of the HR-negative patients.

In the 353 patients with HR-positive disease, CTC-positive patients had a 21.7-fold higher risk for recurrence compared with the CTC-negative group. The median time to recurrence in CTC-positive patients was 1.6 years. A positive CTC assay was not associated with recurrence in the HR-negative group.

The results were somewhat unexpected, according to Dr Sparano. “We were surprised to see that 5% of patients had CTCs about 5 or more years after their initial diagnosis,” he said. “Although we were expecting that CTC-positive patients would have a higher recurrence rate, we weren’t expecting the risk of recurrence to be this high after a relatively short period of time.”

Further study is needed to confirm the clinical utility of this information, he added. For instance, it may be possible that patients can be spared extended adjuvant endocrine therapy if they have a negative CTC assay, indicating a low risk for recurrence.
           
Source:
Sparano JA, O’Neill A, Alpaugh K, et al. Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS6-03.

Related Items
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
Immunotherapy Continues to Gain Momentum in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Last modified: February 26, 2018